Tislelizumab in resectable esophageal squamous cell carcinoma
18 years old ≤75 years old, male or female;
T2-3N0-+M0 or T1bN+M0 thoracic esophageal squamous cell carcinoma (as defined in AJCC 8th Edition) with a definite gastroscopic biopsy.
There is at least one measurable lesion (RECIST1.1 standard);
ECOG PS 0~1;
Esophageal adenocarcinoma was confirmed by histological or cytological pathology;
Previous T cell co-stimulation or immune checkpoint therapy, including but not limited to CTLA-4 inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other T cell-targeting drugs;
A previous or current history of cancer other than esophageal cancer, other than non-melanoma skin cancer that has been treated therapeutically, cervical cancer in situ, or other cancer that has been treated therapeutically and has not shown signs of recurrence for at least 5 years;
Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment or active pneumonia with clinical symptoms or severe lung dysfunction;
Single group
Tislelizumab
DrugTislelizumab 200mg Q3W, D1 ; 2 cycles
Pathological complete response
Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell
Major pathological response
Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell
Objective Response Rate
Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
